Not So Different: A Podcast from The Center for Biosimilars

S6 Ep35: Biosimilars Policy Roundup for July 2024—Podcast Edition

Listen

Description

Show notes


1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara

2. Ahzantive Receives FDA Approval as New Eylea Biosimilar

3. FDA Approves Epysqli as Second Soliris Biosimilar

4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed

5. Biosimilars and Employers: Strategies for Success

6. Learning the Lingo of Biologics and Biosimilars Is Critical

7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings

8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch